Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;85(5):e134-e136.
doi: 10.1016/j.jinf.2022.08.012. Epub 2022 Aug 19.

Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid

Yu Wang  1 , Xubo Chen  2 , Wenying Xiao  3 , Danyang Zhao  4 , Liuliu Feng  5
Affiliations
Comment

Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid

Yu Wang et al. J Infect. 2022 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Authors do not have a conflict of interest among themselves.

Figures

Fig 1
Fig. 1
The evolution of SARS-CoV-2 viral load and the different treatments received. Ct, cycle threshold; GEM-P, methylprednisolone.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Coulson JM, Adams A, Gray LA, Evans A. COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy. J Infect. 2022 - PMC - PubMed
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. - PMC - PubMed
    1. Malden DE, Hong V, Lewin BJ, et al. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022;71(25):830–833. - PubMed
    1. Michael Charness KG, Gary Stack, Judith Strymish, Eleanor Adams, David Lindy, Hiroshi Mohri, David Ho. Symptomatic Omicron SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. PREPRINT (Version 3) available at Research Square.2022.
    1. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv: the preprint server for health sciences.2022.